Low-Carb Versus Mediterranean Diet in PCOS
- Conditions
- Polycystic Ovary Syndrome (PCOS)
- Interventions
- Other: low-carbohydrate dietOther: Mediterranean diet
- Registration Number
- NCT05272657
- Lead Sponsor
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
- Brief Summary
This is a randomized controlled trial of two diets (low-carbohydrate and Mediterranean diet) in the treatment of women with polycystic ovary syndrome (PCOS). The trial assesses the effects of the two diets on clinical, metabolic and hormonal parameters, inflammatory markers and gut microbiota . This study is an interventional, randomized controlled trial, open-labeled.
- Detailed Description
The study aims to clarify the impact of nutritional recommendations for women with polycystic ovary syndrome on clinical, metabolic and hormonal parameters, inflammatory markers and gut microbiota . Women with PCOS are randomized into 2 treatment groups: one group on a low-carbohydrate diet and the other on a Mediterranean diet. The adhearance to a prescribed diet will be controlled through food intake diaries using a mobile application with electronic reporting forms.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 130
-
Women with PCOS between the ages of 18-40 years and with a body mass index of less than or equal to 45.
-
Fulfillment of at least two of the following three criteria for PCOS, adopted by the Rotterdam Consensus in 2003 (Rotterdam ESHRE / ASRM-Sponsored PCOS Consensus Workshop Group):
- signs of hyperandrogenemia - clinical and / or biochemical (increase in the index of free androgens or total testosterone)
- signs of chronic anovulation
- ultrasound signs: the number of follicles in the ovary ≥ 20 and / or ovarian volume ≥ 10 ml in any ovary in the case of gynecological age 8 or more years after menarche.
- The presence of hyperprolactinemia
- Cushing's syndrome
- Ongenital hyperplasia of the adrenal cortex
- Hypothyroidism
- Androgen-producing tumors
- Regular use of drugs and dietary supplements that affect the function of the ovaries
- Adrenal glands
- Metabolism of carbohydrates
- Lipids
- Microbiota composition during the 2 months preceding the study
- Pregnancy
- Lactation
- Significant comorbidities
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description low-carbohydrate diet low-carbohydrate diet subjects in this arm are given detailed instructions and coaching in following a low-carbohydrate diet. Mediterranean diet Mediterranean diet subjects in this arm are given detailed instructions and coaching in following a Mediterranean diet.
- Primary Outcome Measures
Name Time Method 1. Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) index 12 weeks Changes in HOMA-IR index (fasting insulin \[mU/l\] \* fasting glucose \[mmol/L\]/22.5) after intervention
2. Free androgen index 12 weeks Changes in free androgen index \[ (total testosterone level / sex hormone binding globulin (SHBG) level) \* 100\].
- Secondary Outcome Measures
Name Time Method 1. Total testosterone 12 weeks Changes in total testosterone levels \[nmol/L\] in serum after intervention
2. Androstenedione 12 weeks Changes in androstenedione levels in serum after intervention \[ng/ml\]
3. Anti-Müllerian hormone (AMH) 12 weeks Changes in AMH levels in serum after intervention \[ng/ml\]
4. 17-Hydroxyprogesterone (17-OH-progesterone) 12 weeks Changes in 17-OH-progesterone levels in serum after intervention \[ng/ml\]
5. Luteinizing hormone (LH) 12 weeks Changes in LH levels in serum after intervention \[mU/ml\]
6. Follicle-stimulating hormone (FSH) 12 weeks Changes in FSH levels in serum after intervention \[mU/ml\]
7. Insulin 12 weeks Changes in insulin levels in serum as measured with a two-hour oral glucose tolerance test (75 mg glucose in 300 ml water, blood draws at 0 minutes, 60 min and 120 min) \[mU/l\]
8. Glucose 12 weeks Changes in glucose levels in plasma as measured with a two-hour oral glucose tolerance test (75 mg glucose in 300 ml water, blood draws at 0 minutes, 60 min and 120 min) \[mmol/L\]
9. Matsuda index 12 weeks Changes in matsuda index after intervention measured with the formula M=10000/squareroot(glucose0 \* insulin0 \* Mean OGTT glucose concentration \* Mean OGTT insulin concentration)
10. Hirsutism 12 weeks measured by Ferriman-Gallwey-score (mFG-score), ranging from 0 to 36, with 0 being the best possible value and 36 the worst
11. Body-mass-index (BMI) 12 weeks BMI measured with the formula BMI=weight \[kg\]/height² \[m\]
12. waist-to-hip ratio 12 weeks Calculated with the formula: waist circumference/hip circumference
13. Gut microbiome composition 12 weeks Changes in gut microbiome composition measured from stool samples via 16S-RNA gene sequencing
14. Inflammatory markers 12 weeks Changes in inflammatory markers (Cytokines) measured by Human Cytokine/Chemokine/Growth Factor Panel A. 48 plex kit, pg/mL
15. Untargeted metabolomics 12 weeks Serum samples will be analysed to identify biomarkers differentially changing in response to the studied diets using ultra-high performance liquid chromatography (UHPLC).
16. Untargeted metabolomics 12 weeks Serum samples will be analysed to identify biomarkers differentially changing in response to the studied diets using ultra-high performance mass spectrometry (MS).
17. Serum Low-density lipoproteins (LDL) 12 weeks Changes in serum Low-density lipoproteins (LDL), mmol/L
18. Serum high-density lipoproteins (LDL) 12 weeks Changes in serum high-density lipoproteins (LDL), mmol/L
19. Serum triglyceride levels, mmol/L 12 weeks Changes in serum triglyceride levels, mmol/L
20. Ovulation rate 12 weeks Percent of women with ovulation recorded by serial transvaginal ultrasound after 8 weeks of participating in the study
21. Ovarian volume 12 weeks Changes in ovarian volume (cm3) measured by transvaginal ultrasound in early follicular phase or after 3 months of amenorrhea